NCT03875820 2026-03-10FRAMEInstitute of Cancer Research, United KingdomPhase 1 Active not recruiting87 enrolled
NCT07318324 2026-01-06Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerM.D. Anderson Cancer CenterPhase 1 Not yet recruiting31 enrolled
NCT02546531 2021-07-20Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced CancerWashington University School of MedicinePhase 1 Completed43 enrolled
NCT04201145 2020-11-17Pembrolizumab + Defactinib In Pleural MesotheliomaDana-Farber Cancer InstitutePhase 1 Withdrawn